HepG2.2.15 Cells

The HepG2.2.15 cell line is a derivative of the HepG2 cell line, which originates from a human hepatoblastoma, a type of liver cancer. These cells are particularly noteworthy for their ability to stably express hepatitis B virus (HBV) particles, making them invaluable in the study of HBV biology and the development of antiviral drugs. HepG2.2.15 cells maintain many of the characteristics of hepatocytes, including the production of proteins such as albumin and alpha-fetoprotein, which are critical for liver function. Additionally, they possess a polygonal shape and form tight clusters, resembling liver tissue structure.
One of the primary uses of the HepG2.2.15 cell line is in researching HBV replication and pathogenesis. These cells are transfected with the HBV genome, leading to the continuous production of viral particles. This feature makes them an ideal model for studying the lifecycle of HBV and the effects of various antiviral agents. Researchers utilize HepG2.2.15 cells to screen for potential therapeutic compounds, investigate viral entry and replication mechanisms, and understand the host’s immune response to HBV infection. The cell line’s ability to produce HBV also allows for the study of viral mutations and resistance patterns, which is crucial for developing effective treatments.